Top Tech Companies (2,065)
Don't see your company?
Create a company profile
The way we see it, the impossible is not impossible. It’s simply what hasn’t been achieved yet. For more than 30 years, we’ve pursued it, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases. Creating Possible drives everything we do. It’s evident in our mission and core values. This is how we built a culture of excellence that is fueled by a passion for improving lives of people around the world. For us, nothing is impossible – because of the people we work with, the communities we stand with and the partners we push forward with. Our ~12,000 employees band together through science, grit, compassion and courage to prove the impossible wrong. At Gilead, the tangible results of your contributions are evident. Where every individual matters. Where all employees can enhance their skills through ongoing development. And where we start every day with one question: “What’s next?” Social Media Guidelines: https://gilead.inc/3t1m7d5
Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast’s prime biotech hub in South San Francisco.
AltPep develops early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach. Our lead program aims to identify Alzheimer’s Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.
Founded in Indianapolis in 2014, Genezen is focused on supporting the demands of the current and future gene and cell therapy manufacturing market worldwide— making viral vector production accessible to both early-stage, growth-oriented companies and established industry leaders. Genezen offers early-phase process development, GMP lentiviral vector production, retroviral vector production, and analytical testing services, building on the company's expansive knowledge and experience in the industry and working with the nation's leading institutions. For more information, or to learn more about services offered in Genezen's new cGMP facility, please visit our website: www.genezen.com
Fluxergy was founded 10 years ago with a vision to democratize the world of laboratory testing, by making testing more accessible and affordable. Fluxergy’s platform technology enables us to understand our world and our health in ways that were never possible before. Fluxergy is developing a platform with multi-modal detection technologies which bring the variety of tests found in the central lab to the palm of your hand – This includes molecular testing like PCR, Immunochemistry and chemistry testing, and microscopy testing such as cytometry. Fluxergy’s platform vision is the detection of genes, proteins, small molecules, and cells with the same analyzer. The automated, sample-to-answer workflows can be customized for specific sample and testing methods.
As a world-leading drug device combination solutions specialist, our purpose of putting patients first enables us to design and manufacture devices that maximize treatment efficacy. We are the utmost holistic partner and help our customers succeed in the sprint to market. From early device strategy to state-of-the-art manufacturing, we're committed to the highest quality standards. Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfill our mission. Nemera’s services and products cover five key delivery routes: ● Ophthalmic (preservative-free multidose eyedroppers) ● Nasal, Buccal, Auricular (pumps, valves and actuators for sprays), ● Inhalation (pMDI, DPIs) ● Dermal and Transdermal (airless & atmospheric dispensers) ● Parenteral (auto-injectors, pens, safety devices & implanters) At Nemera, we put patients first when designing, developing and manufacturing drug delivery devices because we know that accurate dosing and ergonomics contribute to patients completing their treatment. Whether they are Nemera proprietary or customer owned, our devices receive the utmost care because we know how critical they are for patients’ health and well-being. Interested in joining a team that truly enjoys working together and prides itself on being at the forefront of innovation and quality? Do you always go the extra mile to deliver on your commitments? Want to feel proud of your work because it improves patients’ lives? If you're ready to help us grow our business and make a real difference, please visit https://www.nemera.net or contact us at [email protected].
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours.
Atavistik Bio is a new, privately-held biopharmaceutical company focused on the discovery and development of novel therapies for metabolic diseases and cancer. Our high-throughput platform for the unbiased identification of metabolite-protein interactions will enable the discovery of first-in-class drugs inspired and empowered by nature’s own mechanisms of allosteric control. Our unique approach marries this validated platform with structure-aided drug design capabilities and cutting-edge insights into the regulation of metabolic systems to apply to genetically validated targets.
A trusted partner at nearly three million customer locations, Ecolab (ECL) is the global leader in water, hygiene and infection prevention solutions and services. With annual sales of $12 billion and more than 44,000 associates, Ecolab delivers comprehensive solutions, data-driven insights and personalized service to advance food safety, maintain clean and safe environments, optimize water and energy use, and improve operational efficiencies and sustainability for customers in the food, healthcare, hospitality and industrial markets in more than 170 countries around the world. For more Ecolab news and information, visit www.ecolab.com, or follow us on twitter.com/ecolab, facebook.com/ecolab or instagram.com/ecolab_inc.
Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Taking a foundationally different approach to thrombus reduction, the company manufactures intravenous catheters from a hydrophilic material which retains significant amounts of water. Engineered to mimic the body’s natural chemistry, Access Vascular catheters are designed to evade the foreign body response and complications that come with it. Our cleared products are HydroPICC®and HydroMID®. For more information, please visit www.accessvascularinc.com.
Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation chemoproteomics RAPID platform to discover medicines for highly validated, challenging-to-drug targets to treat diseases with high unmet need. Jnana is focused on developing first- and best-in-class therapies to treat a wide range of diseases, including rare diseases, immune-mediated diseases and cancer. Jnana’s wholly owned lead program is a potential first-in-class oral approach, targeting an allosteric site on the phenylalanine transporter SLC6A19, for the treatment of phenylketonuria (PKU), a rare genetic metabolic disease. Located in Boston, Jnana brings together scientific leaders in small molecule drug discovery and development, a highly experienced management team and the backing of leading life science investors Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures and AbbVie Ventures. For more information, please visit www.jnanatx.com and follow us on Twitter and on LinkedIn.
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. To learn more, visit www.modernatx.com. This Moderna page is not the appropriate place to report adverse events (side-effects) for any products. If you are or someone you know is experiencing a side effect, please reach out to your healthcare professional. Moderna is continuously monitoring the safety of its products. We encourage you to report any side effects directly to us at 1‑866‑MODERNA (1‑866‑663‑3762).
Our mission is to cure disease by writing the code of life
Scout Clinical’s mission is to make it easier for patients to participate in clinical trials. From travel arrangements and payment management to regulatory review and special services, we do it all.
Pendulum is committed to developing novel interventions that target the human microbiome to improve the lives of patients suffering from a variety of diseases. Our targeted formulations of natural bacterial strains help to rebalance the microbiome which restores and improve one’s health.
Andes empowers biology to enable positive action against climate change
Rapid Micro Biosystems is an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. We are the trusted partner in quality control microbiology automation, enabling our customers to improve and save lives. This vision has been realized with the development of the Growth Direct® System. Our Growth Direct® platform automates and modernizes the antiquated, manual quality control microbiology testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct® platform brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line QC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. Our company values guide us in our vision: Customer Driven – We are committed to providing our customers with the highest quality products and services Respect – We welcome and embrace our differences to create a trusting environment Grit – We are determined to turn challenges into successes. One RMB – We operate as one team, committed to our shared purpose. The company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands
Biorasi is a customer-focused, full-service, contract research organization (CRO) that delivers fast and flexible solutions across global clinical trials to maximize speed-to-market for its sponsors. As the leader in neurology, nephrology, dermatology, and the rare and urgent disease market, Biorasi sets new standards for speed, agility, and quality in patient enrollment, decentralized trials, and data transparency. It is Biorasi’s mission to be a catalyst for growth, innovation, and evolution in the field of clinical research – moving the industry forward while improving results for our partners and outcomes for their patients. Our culture is based on our strong commitment to building true partnerships with our sponsors. We approach all of our trials with urgency, commitment, and resolve. Established in 2002, Biorasi is headquartered in Aventura, FL, with office-based teams around the globe. From its regional presences, Biorasi is able to directly support studies in the Americas, Europe, and APAC. We have received multiple accolades including placement in the INC 500 and 5000 list of fastest-growing companies in America, Frost and Sullivan’s Entrepreneurial Company of the Year for the CRO Industry, and the CRO Leadership Award from Life Science Leader magazine.
Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Cancer. Diabetes. Alzheimer’s. Heart Disease. Parkinson’s. The Jackson Laboratory (JAX) leads the search to cure diseases rooted in our DNA. Founded in 1929, we are an NCI-designated Cancer Center since 1983 and an independent 501(c)3 nonprofit research organization with over 90 years of experience in genetics and genomics research. JAX blends the brightest minds with state-of-the-art resources to accelerate discovery. Areas of Discovery (75+ Principal Investigators, >250 Ph.D.s, M.D.s, and D.V.M.s): • Cancer: We are a National Cancer Institute designated Cancer Center focusing on cancer initiation, progression, prevention and therapies. • Developmental/reproductive biology: birth defects, Down syndrome, osteoporosis, fertility • Immunology: HIV-AIDS, anemia, autoimmunity, cancer immunology, immune disorders, lupus, transplant rejection • Metabolic diseases: atherosclerosis, cardiovascular disease, diabetes, high blood pressure, obesity, microbiome • Neurobiology: blindness, Parkinson’s, Alzheimer’s, deafness, epilepsy, glaucoma, macular degeneration, neurodegenerative diseases • Neurobehavioral disorders: autism, addiction, depression Supporting Global Research: • The JAX Mouse Repository and Scientific Services are among the premier resources available for biomedical research. Committed to Education: • Summer Student Program (undergrad & high school) • Teaching the Genome Generation Short Course • Ph.D. programs: U. Maine, Tufts University and U. Connecticut • Courses, Conferences and Workshops
